Newsroom | 6051 results

SANTA CLARA, Kalifornien--(BUSINESS WIRE)--TSMC (TWSE: 2330, NYSE: TSM) hat heute auf dem North America Technology Symposium des Unternehmens seine nächste hochmoderne Logik-Prozesstechnologie A14 vorgestellt. A14 ist eine bedeutende Weiterentwicklung des branchenführenden N2-Prozesses von TSMC und soll durch eine schnellere Rechenleistung und höhere Energieeffizienz die KI-Transformation vorantreiben. Auch Smartphones werden durch A14 um integrierte KI-Funktionen erweitert und dadurch noch int...

SANTA CLARA, Calif.--(BUSINESS WIRE)--TSMC (TWSE: 2330, NYSE: TSM) presentó hoy su última tecnología de vanguardia de fabricación de chips, llamada A14, en el simposio de tecnología llevado a cabo por la compañía. La tecnología A14 representa un avance significativo con respecto al proceso N2 de TSMC, que lideraba el sector, y ha sido diseñada para impulsar la transformación de la inteligencia artificial al ofrecer una computación más rápida y una mayor eficiencia energética. También se espera...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Expands Universal Adapter Portfolio with Launch of High Throughput UDI Adapter System...

SANTA CLARA, California--(BUSINESS WIRE)--Nel corso del North America Technology Symposium, TSMC (TWSE: 2330, NYSE: TSM) ha presentato oggi la sua prossima tecnologia all'avanguardia di processo logico, A14. Tale tecnologia rappresenta un notevole progresso rispetto al processo leader del settore N2 di TSMC, ed è progettata per guidare la trasformazione dell'IA, offrendo un'elaborazione di calcolo più rapida e una maggiore efficienza energetica. Si prevede inoltre che potenzierà gli smartphone...

SANTA CLARA, Calif.--(BUSINESS WIRE)--TSMC (TWSE : 2330, NYSE : TSM) a dévoilé aujourd’hui sa prochaine technologie de pointe en matière de logique, A14, lors de son symposium technologique en Amérique du Nord. Représentant une avancée majeure par rapport au procédé N2 de TSMC, déjà leader de l’industrie, la technologie A14 est conçue pour faire progresser la transformation par l’intelligence artificielle en offrant des performances de calcul accrues et une meilleure efficacité énergétique. Ell...

SANTA CLARA, Calif.--(BUSINESS WIRE)--TSMC (TWSE: 2330, NYSE: TSM) heeft vandaag zijn volgende geavanceerde logische procestechnologie, A14, onthuld op het North America Technology Symposium van het bedrijf. A14 vertegenwoordigt een aanzienlijke vooruitgang ten opzichte van TSMC's toonaangevende N2-proces en is ontworpen om de AI-transformatie te bevorderen door de levering van sneller computerwerk en hogere energie-efficiëntie. Verwacht wordt dat het ook goed zal zijn voor smartphones door hun...

TOKYO--(BUSINESS WIRE)--Mitsubishi Electric Corporation and Nanofiber Quantum Technologies Inc. (NanoQT) announced today the immediate launch of a joint demonstration aimed at establishing interconnection technologies for neutral-atom quantum computers. Neutral-atom quantum computers offer significant advantages in scalability due to their capacity for high integration and through the use of optical tweezers for flexible control of atom arrangement. However, the number of quantum bits (qubits)...

SANTA CLARA, Calif.--(BUSINESS WIRE)--TSMC (TWSE: 2330, NYSE: TSM) today unveiled its next cutting-edge logic process technology, A14, at the Company’s North America Technology Symposium. Representing a significant advancement from TSMC’s industry-leading N2 process, A14 is designed to drive AI transformation forward by delivering faster computing and greater power efficiency. It is also expected to enhance smartphones by improving their on-board AI capabilities, making them even smarter. Plann...

DUBLIN--(BUSINESS WIRE)--The "Pharmaceutical Excipients - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Pharmaceutical Excipients was valued at USD 10.2 Billion in 2024 and is projected to reach USD 13.3 Billion by 2030, growing at a CAGR of 4.5% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. Pharmaceutical exci...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vizgen, Inc., the life sciences company revolutionizing spatial genomics and proteomics research and driving innovation in spatial multi-omics, today announced the broad global commercial availability of MERFISH 2.0™, a next-generation spatial transcriptomics chemistry designed to drive breakthroughs in foundational biological research. The company also announced the expansion of fully configurable OmniVUE™ spatial proteomics panels with validated biomarkers a...